Try Alerts Free   |   Login
Health Care › Pharmaceutical Preparations

Evoke Pharma (EVOK) Financials and Smart Investor 13F Alerts

See how revenue, income, cash flow, and balance sheet financials have changed over 28 quarters since 2014. Compare with EVOK stock chart to see long term trends.

EVOK stock compared to

EVOK Income Statement

Research & Development Expense:103846
Total Operating Expenses:2232106
Operating Income:-2209086
Net Income:-2267862
Earnings Per Share, Basic:-0.09
Shares Outstanding, Basic Avg:25492169

EVOK Cash Flow

Operating Activities Net Income:
Net Cash from Operations:-1711504
Net Cash from Financing Activities:3499787
Net Change in Cash & Equivalents:1788283

EVOK Balance Sheet

Cash and Cash Equivalents:8068939
Inventories:236480
Total Current Assets:9280792
Total Assets:9434048
Total Short-Term Liabilities:7535677
Total Liabilities:12648671

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Vanguard Group Inc
1,033,707 sh
376,779 sh
57%
$4,848
$2,523
Blackrock Inc.
128,275 sh
-71,153 sh
-36%
$601
-$105
Morgan Stanley
92,920 sh
66,443 sh
251%
$436
$343
Northern Trust Corp
37,227 sh
-211 sh
-1%
$175
$42
Sabby Management, LLC
22,382 sh
22,382 sh
NEW
$105
$105
Renaissance Technologies LLC
22,300 sh
22,300 sh
NEW
$105
$105
Charles Schwab Investment Management Inc
14,398 sh
14,398 sh
NEW
$68
$68
Goldman Sachs Group Inc
0 sh
-35,174 sh
-100%
$0
-$125
Proequities, Inc.
0 sh
 
$0

Data imported from Evoke Pharma Inc SEC filings. Check original filings before making any investment decision.